



# Treatment Enrollment Form

Toll Free Phone: 1-866-665-3244  
Toll Free Fax: 1-844-461-3244

Email: [infusions@firstchoiceiv.com](mailto:infusions@firstchoiceiv.com)  
Forms: [firstchoiceiv.com/infusion-services-forms/](http://firstchoiceiv.com/infusion-services-forms/)

## Patient Information

Patient Name: \_\_\_\_\_ SSN#: \_\_\_\_\_ Gender: Male Female  
DOB: \_\_\_\_\_ Language Preference: English Spanish Other \_\_\_\_\_  
Street Address: \_\_\_\_\_ Apt #: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Primary Phone: \_\_\_\_\_ E-mail Address: \_\_\_\_\_  
Emergency/guardian Contact: \_\_\_\_\_ Emergency/guardian Phone: \_\_\_\_\_

## Insurance Information

Please attach front and back of patient's insurance cards or complete the information below

Insurance Company: \_\_\_\_\_ Company Phone: \_\_\_\_\_  
Name of Insured: \_\_\_\_\_ Relationship to Patient: \_\_\_\_\_  
Employer: \_\_\_\_\_ ID#: \_\_\_\_\_ Group/Policy#: \_\_\_\_\_  
Prescription Card: Yes No Carrier: \_\_\_\_\_ Group/Policy#: \_\_\_\_\_  
Patient eligible for Medicare: Yes No Patient has secondary insurance: Yes No

## Prescriber Information

Prescriber's Name: \_\_\_\_\_ Hospital/Group: \_\_\_\_\_  
Street Address: \_\_\_\_\_ Office Phone: \_\_\_\_\_  
City, State, Zip: \_\_\_\_\_ Office Fax: \_\_\_\_\_  
E-mail Address: \_\_\_\_\_ Office Contact Person: \_\_\_\_\_  
NPI#: \_\_\_\_\_ DEA#: \_\_\_\_\_ State License#: \_\_\_\_\_

## Prior Authorization Information

- Patient demographic page
- Patient SSN
- Most recent H&P
- Most recent labs
- Copy of any/all insurance cards on file, both medical and pharmacy

Most Specialty Medications require insurance verification and Prior Authorization. At First Choice Wellness Centers, we do that work for you. Please send all the above documentation so we may quickly expedite these tasks for you without taking up your valuable time.

Confidentiality Statement: The information contained in the following document(s) is legally privileged and confidential information intended only for the use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any viewing, dissemination, distribution, or copy of the attached document(s) is strictly prohibited. If you have received and/or are viewing attached document(s) in error, please immediately notify the sender and arrange for the immediate return or destruction of the attached document(s).

**Patient Information**

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

**Uplizna**

Infusion Order Form

**Clinical Information**

Primary ICD-10 Code: \_\_\_\_\_ Weight: \_\_\_\_\_ (kg /lbs ) Height: \_\_\_\_\_ (cm /in )

Patient previously treated for this condition: Yes No Patient currently on treatment: Yes No

Known Allergies: \_\_\_\_\_

All ICD-10 codes for any/all related diagnosis (if not listed in H&amp;P): \_\_\_\_\_

**Prescriber must indicate the following requirements have been met (please provide documentation)****Quantitative immunoglobulins within normal limits****Latent TB screening negative****Anti-aquaporin-4 (AQP4) antibody positive (required)****HBV screening negative****If any the above are not checked, attach treatment/consultation notes clearing patient for inebilizumab-cdon therapy****Pre-medication Information****Acetaminophen 500mg to 650mg PO, once 30 minutes to 60 minutes prior to infusion****Methylprednisolone 80mg to 125mg IV, once 30 minutes prior to infusion****Diphenhydramine 25mg to 50mg PO, once 30 minutes to 60 minutes prior to infusion****Medication Information**

Medication	Note: PFS is abbreviation for Prefilled Syringes	Directions/Frequency	IV Access Type:	Peripheral	PICC	Port								
<b>Uplizna (inebilizumab-cdon)</b>	Dilute <b>inebilizumab-cdon 300 mg/30 mL in 250 mL 0.9% sodium chloride</b> and administer intravenously using a sterile, in-line, low protein-binding <b>0.2- or 0.22-micron filter</b> using rates in table below.	On Day 1 and Day 15; repeat in 6 months (from Day 1) Every 6 months (date of last treatment: _____)												
<table border="1"> <thead> <tr> <th>Elapsed Time (minutes)</th> <th>Infusion Rate</th> </tr> </thead> <tbody> <tr> <td>0-30</td> <td>42mL/hr</td> </tr> <tr> <td>31-60</td> <td>125mL/hr</td> </tr> <tr> <td>61 to completion</td> <td>333mL/hr</td> </tr> </tbody> </table>		Elapsed Time (minutes)	Infusion Rate	0-30	42mL/hr	31-60	125mL/hr	61 to completion	333mL/hr	<b>Pre-infusion</b>				
Elapsed Time (minutes)	Infusion Rate													
0-30	42mL/hr													
31-60	125mL/hr													
61 to completion	333mL/hr													
Flush with 0.9% sodium chloride at the completion of infusion		Assess for contraindications; hold infusion and notify provider for signs/symptoms of active infection, planned or recent invasive/surgical procedure, receipt of live or live-attenuated vaccines within 4weeks, chance of pregnancy, or signs/symptoms of PML (new or worsening unilateral weakness, confusion or changes in vision, thinking, memory, balance, or personality/mood). Obtain vital signs at baseline and with rate changes Establish vascular access If infusion-related reaction occurs, stop infusion and treat per orders/protocol as clinically indicated.												

**Notes****In event of infusion reaction, follow Adverse Reaction Protocols for treatment.****Monitor patient for hypersensitivity reaction for a period of 60 minutes following infusion.****Record vital signs immediately following infusion and prior to discharge.****Leave IV in place for observation period; remove prior to discharge.****Provide patient with discharge instructions.****Fax treatment notes to provider at \_\_\_\_\_****Infusion reaction special orders: \_\_\_\_\_****Prescriber Information**

Prescriber Name: \_\_\_\_\_ Prescriber Phone: \_\_\_\_\_

By signing below, I certify that the above therapy is medically necessary, and I authorize treatment.

Substitution allowed \_\_\_\_\_

Dispense as written \_\_\_\_\_

Date: \_\_\_\_\_

Date: \_\_\_\_\_

Confidentiality Statement: The information contained in the following document(s) is legally privileged and confidential information intended only for the use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any viewing, dissemination, distribution, or copy of the attached document(s) is strictly prohibited. If you have received and/or are viewing attached document(s) in error, please immediately notify the sender and arrange for the immediate return or destruction of the attached document(s).